This page does not organise the public argument into tribes. Each row is a claim, the current evidence, the remaining uncertainty, and the sources. Where the literature is contested, both sides stay on the table.
01 · The claim
Everyone is a little ADHD.
What current evidence says
Attentional lapses are ordinary. ADHD, as used in clinical guidelines, is not ‘sometimes distracted’. It is a persistent pattern of inattention and/or hyperactivity-impulsivity, present across settings, with onset in development, causing impairment. International consensus treats ADHD as a valid diagnosis, not a personality quirk with better branding (Faraone et al., 2021; AADPA 2022).
What remains uncertain
Where the boundary is drawn will always have an edge. Impairment thresholds, informant quality and cultural context affect who meets criteria. That is true of most psychiatric and developmental diagnoses. It is not evidence that the construct is empty.
Clinical guidelines and international consensus reject a moral account of ADHD. Heritable neurodevelopmental differences, functional impairment, and treatment response (including to stimulant medicine versus placebo in trials) are not the fingerprint of laziness. Parenting quality is not the cause of ADHD, though any family can be strained by unsupported difficulty (Faraone et al., 2021; AADPA 2022; Cortese et al., 2018).
What remains uncertain
Skills, sleep, environment and comorbidity all affect how impairment shows. A supportive structure can reduce harm without proving that the original difficulty was a character defect.
ADHD often persists into adulthood. Compensation, intelligence, supportive context and later-life collapse of scaffolding can delay recognition for decades. Adult diagnosis is described in Australian and international guidance as legitimate clinical work, not a consolation prize (Faraone et al., 2021; AADPA 2022; NICE NG87).
What remains uncertain
High-achieving presentations are harder to assess well. Success in one domain does not measure the cost paid in sleep, relationships, or the rooms the person no longer enters.
Adult recognition of ADHD has increased. PBS dispensing of ADHD medicines in Australia rose sharply, especially after 2018–19 (AIHW, 2025). Increased help-seeking, reduced stigma, better adult criteria, and social-media conversation can all raise demand. Rising demand is real. A 2025 systematic review covering 40 studies across 17 countries found that the highest-quality evidence did not indicate an increase in underlying ADHD prevalence since 2020, while incidence showed some variability during the COVID-19 pandemic (Martin et al., 2025). The authors also reported substantial limitations in the prevalence literature.
More people being recognised is observable.
More people seeking assessment is observable.
More people receiving medication is observable.
A sudden increase in the underlying prevalence of ADHD is not currently established.
Competing evidence
Some clinicians and commentators worry about over-diagnosis, brief assessments, and self-diagnosis from short videos. Those concerns are part of the literature and the public argument. They do not, by themselves, establish that adult ADHD is invented. Estimated adult prevalence in international syntheses is in the low single-digit percentages; a rise in treated patients toward that range is compatible with previously missed people arriving, with over-identification, or with both. Dispensing is not prevalence. Waitlists are not prevalence. Social media is not a randomised trial.
What remains uncertain
We do not have a clean Australian census of true underlying prevalence over time. Until we do, ‘more diagnoses’ should be read as more diagnoses — then inspected, not mocked or celebrated in advance. Martin et al. themselves note reporting delays, missing healthcare data, missing school-level data, and that only four included studies were at low risk of bias.
An autism diagnosis explains every psychiatric symptom.
What current evidence says
Autistic people have higher rates of co-occurring mental health diagnoses than the general population, including ADHD, anxiety, sleep disorders and depression (Lai et al., 2019). Co-occurrence is common. It is not a licence to stop looking. Mood elevation, trauma, eating disorders and psychosis-spectrum symptoms still require their own assessment. Diagnostic overshadowing — attributing new or residual symptoms automatically to the known developmental diagnosis — is a documented failure mode, originally described in intellectual disability and relevant wherever a label becomes a ceiling on curiosity (Jopp & Keys, 2001; Young et al., 2020).
What remains uncertain
Some psychiatric symptoms in autistic people are shaped by sensory load, masking and burnout rather than a second diagnosis. Distinguishing those from a co-occurring disorder is clinical work. A website cannot do it.
People seeking diagnoses are simply collecting labels.
What current evidence says
A later diagnosis does not automatically invalidate an earlier one. Depression may have been real; ADHD may also have been present; autism may later explain experiences neither fully accounted for. Sequential recognition is well described, including later autism identification when ADHD was named first (Miodovnik et al., 2015). Seeking a more complete model is not the same as souvenir-hunting.
Competing evidence
Assessment quality varies. Brief, high-throughput private pathways can over-identify; inaccessible public pathways can under-identify. Both can be true in the same country. Neither fact turns the person in the waiting room into a collector.
What remains uncertain
We cannot know, from a social-media post, whether a given person is looking for understanding, for accommodations, for stimulants, or for all of these. Motive-reading is not epidemiology.
Stimulant medication affects everyone in the same way.
What current evidence says
Network meta-analysis supports stimulant efficacy for core ADHD symptoms at the population level, with differences between medicines, ages and tolerability (Cortese et al., 2018). Individual response varies. Appetite, sleep, mood, rebound and uncommon psychiatric reactions are not evenly distributed. Observational data have associated amphetamine, more than methylphenidate, with uncommon incident psychosis in young people (Moran et al., 2019). A class effect is not a uniform biography.
What remains uncertain
Why one person feels quieter and another feels wired is only partly mapped. Sleep, dose, formulation, comorbidity and expectation all occupy the same fortnight.
Lived experience is meaningless because it is anecdotal.
What current evidence says
Personal experience is valuable evidence about an individual's experience. It is not automatically evidence of population-level causality. Qualitative research has made emotional blunting and autistic burnout speakable in clinics that did not have words for them (Price et al., 2009; Raymaker et al., 2020). Different methods answer different questions. A diary is not a failed trial.
Competing evidence
Unstructured online testimony can spread both genuine patterns and contagious explanations. That is a reason to classify evidence, not a reason to discard first-person data.
What remains uncertain
How to combine n=1 timelines with population evidence without letting either silence the other is an open scientific and ethical problem. This site exists to keep that problem visible.
